<DOC>
	<DOCNO>NCT01765881</DOCNO>
	<brief_summary>For 10 % pregnancy , necessary induce delivery medical reason . Prostaglandins alone use perform cervical ripening case immature cervix . In France , dinoprostone approve medication . It form gel sustain release device whose effectiveness side effect comparable . The vaginal misoprostol marketing authorization France , sometimes use . Some data scientific literature show use low-dose ( 25 mcg ) vaginally lead complication , least effective seem cost-effective compare dinoprostone . Misoprostol dose route administration recommend American College Obstetricians Gynecologist ( ACOG ) , Grade A ( ACOG Practice Bulletin August 2009 ) . This case France ( French HAS 2008 Guidelines induction labor ) . According HAS , investigator still lack data large sample confirm benefit misoprostol 25 mcg vaginally , term efficiency , rate cesarean section , low cost compare dinoprostone . The primary objective demonstrate non-inferiority vaginal misoprostol 25 mcg vs. dinoprostone term cesarian section occurence non-inferiority margin +5 % difference .</brief_summary>
	<brief_title>Comparison Between 25 µg Vaginal Misoprostol v Slow Release Pessary PGE2</brief_title>
	<detailed_description>To show experimental treatment ( 25μg intravaginal misoprostol ) use induction labor singleton woman ≥ 36 week gestation unfavorable cervix clinically statistically inferior reference treatment , ie intravaginal dinoprostone sustain release ( 10mg ) , term cesarian sectionto compare cost-effectiveness assess differential tolerance two strategy . Non-inferiority demonstrate upper limit 90 % -bilateral confidence interval difference cesarian section rate ( misoprostol - dinosprostone ) 5 % intention-to-treat analysis per-protocol analysis . If non-inferiority demonstrate , secondary analysis , superiority misosprostol test . Orther secondary objective assess cost-effectiveness , tolerance , maternal satisfaction efficacy endpoint two strategy .</detailed_description>
	<mesh_term>Misoprostol</mesh_term>
	<mesh_term>Dinoprostone</mesh_term>
	<criteria>singleton pregnancy Cephalic presentation Bishop ≤ 5 ≤ 3 uterine contraction / 10 mn ≥ 36 week gestation Personally sign date informed consent document History cesariansection uterine scar deceleration Cardiotocogram ( CTG ) placenta praevia bleed chorioamnionitis Fetal weight US ≥4500 g Contraindication vaginal delivery Hystory myomectomy Herpes primoinfection recurrence Allergy prostaglandin</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Induction labor</keyword>
	<keyword>cervical ripening</keyword>
	<keyword>misoprostol ,</keyword>
	<keyword>prostaglandin</keyword>
	<keyword>cost-effectiveness</keyword>
</DOC>